Cervarix Passes Safety Hurdles; FDA Ponders Breadth of Protection Claim
Executive Summary
GlaxoSmithKline surmounted the final safety hurdles for its human papillomavirus vaccine Cervarix at a landmark September 9 FDA advisory committee review of the adjuvanted product
You may also be interested in...
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.